Drug intelligence / Profile preview

nicorandil

Development stage
Phase 4
Lead developer
Chugai Pharmaceutical
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Nicorandil is a small molecule antianginal drug used primarily for the prevention and treatment of chronic stable angina pectoris. It acts as both a potassium channel opener (specifically ATP-sensitive potassium channels) and a nitrate donor. Through these dual mechanisms, nicorandil causes vasodilation of both arterial and venous vessels—relaxing vascular smooth muscle to increase coronary blood flow and reduce cardiac preload and afterload. The activation of ATP-sensitive potassium channels leads to hyperpolarization of smooth muscle cells, while the nitrate moiety increases cyclic GMP levels via stimulation of guanylate cyclase, further promoting vasodilation. Nicorandil is typically prescribed when other heart medicines are ineffective or unsuitable[1][2][5][8].

Brand names
IkorelAngedilDancorNikoran
Other names
nicorandil extended releaseAUX-001AUX001AUX 001
02

Targets

KATP channel (ATP-sensitive potassium channel)sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on nicorandil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicorandil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call